Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors

Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors

BackgroundThe clinical value of postoperative adjuvant therapy (PAT) for hepatocellular carcinoma (HCC) remains unclear. This study aimed to explore the effect of PAT with tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies on the surgical outcomes of HCC patients with high-risk recurrent fac...

Full description

Bibliographic Details
Main Authors: Jian Li, Wen-qiang Wang, Rong-hua Zhu, Xing Lv, Jin-lin Wang, Bin-yong Liang, Er-lei Zhang, Zhi-yong Huang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Immunology
Subjects:
hepatocellular carcinoma
high-risk recurrent factors
tyrosine kinase inhibitors
anti-PD-1 antibodies
postoperative adjuvant therapy
surgical outcomes
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1202039/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1202039/full

Similar Items